BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Common plasma protein marker LCAT in aggressive human breast cancer and canine mammary tumor

  • Park, Hyoung-Min (Department of Biochemistry, BK21 Plus and Research Institute for Veterinary Science, School of Veterinary Medicine, Seoul National University) ;
  • Kim, HuiSu (Department of Biochemistry, BK21 Plus and Research Institute for Veterinary Science, School of Veterinary Medicine, Seoul National University) ;
  • Kim, Dong Wook (Department of Biochemistry, BK21 Plus and Research Institute for Veterinary Science, School of Veterinary Medicine, Seoul National University) ;
  • Yoon, Jong-Hyuk (Neurodegenerative Disease Research Group, Korea Brain Research Institute) ;
  • Kim, Byung-Gyu (Center for Genomic Integrity, Institute for Basic Science, UNIST) ;
  • Cho, Je-Yoel (Department of Biochemistry, BK21 Plus and Research Institute for Veterinary Science, School of Veterinary Medicine, Seoul National University)
  • Received : 2020.10.31
  • Accepted : 2020.11.24
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Breast cancer is one of the most frequently diagnosed cancers. Although biomarkers are continuously being discovered, few specific markers, rather than classification markers, representing the aggressiveness and invasiveness of breast cancer are known. In this study, we used samples from canine mammary tumors in a comparative approach. We subjected 36 fractions of both canine normal and mammary tumor plasmas to high-performance quantitative proteomics analysis. Among the identified proteins, LCAT was selectively expressed in mixed tumor samples. With further MRM and Western blot validation, we discovered that the LCAT protein is an indicator of aggressive mammary tumors, an advanced stage of cancer, possibly highly metastatic. Interestingly, we also found that LCAT is overexpressed in high-grade and lymph-node-positive breast cancer in silico data. We also demonstrated that LCAT is highly expressed in the sera of advanced-stage human breast cancers within the same classification. In conclusion, we identified a possible common plasma protein biomarker, LCAT, that is highly expressed in aggressive human breast cancer and canine mammary tumor.

Keywords

References

  1. Woolston C (2015) Breast cancer. Nature 527, S101 https://doi.org/10.1038/527S101a
  2. Hoag H (2015) Molecular biology: marked progress. Nature 527, S114-115 https://doi.org/10.1038/527S114a
  3. Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N and Weber W (2016) Molecular imaging of biomarkers in breast cancer. J Nucl Med 57 Suppl 1, 53S-59S https://doi.org/10.2967/jnumed.115.157909
  4. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25, 5287-5312 https://doi.org/10.1200/JCO.2007.14.2364
  5. Geyer PE, Holdt LM, Teupser D and Mann M (2017) Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13, 942 https://doi.org/10.15252/msb.20156297
  6. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE and Watanabe MA (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers 2014, 513158 https://doi.org/10.1155/2014/513158
  7. Salas Y, Marquez A, Diaz D and Romero L (2015) Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: a growing animal health problem. PLoS One 10, e0127381 https://doi.org/10.1371/journal.pone.0127381
  8. Dantas Cassali G, Cavalheiro Bertagnolli A, Ferreira E, Araujo Damasceno K, de Oliveira Gamba C and Bonolo de Campos C (2012) Canine mammary mixed tumours: a review. Vet Med Int 2012, 274608 https://doi.org/10.1155/2012/274608
  9. de Ronde JJ, Lips EH, Mulder L et al (2013) SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res Treat 137, 213-223 https://doi.org/10.1007/s10549-012-2340-x
  10. Xie X, Zhao J, Xie L et al (2019) Identification of differentially expressed proteins in the injured lung from zinc chloride smoke inhalation based on proteomics analysis. Respir Res 20, 36 https://doi.org/10.1186/s12931-019-0995-0
  11. Dobiasova M and Frohlich JJ (1999) Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. Clin Chim Acta 286, 257-271 https://doi.org/10.1016/S0009-8981(99)00106-0
  12. Subbaiah PV, Liu M and Witt TR (1997) Impaired cholesterol esterification in the plasma in patients with breast cancer. Lipids 32, 157-162 https://doi.org/10.1007/s11745-997-0020-5
  13. Rakha EA, Aleskandarany MA, Toss MS et al (2018) Impact of breast cancer grade discordance on prediction of outcome. Histopathology 73, 904-915 https://doi.org/10.1111/his.13709
  14. Rahman M and Mohammed S (2015) Breast cancer metastasis and the lymphatic system. Oncol Lett 10, 1233-1239 https://doi.org/10.3892/ol.2015.3486
  15. Lindblad-Toh K, Wade CM, Mikkelsen TS et al (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438, 803-819 https://doi.org/10.1038/nature04338
  16. Abdelmegeed SM and Mohammed S (2018) Canine mammary tumors as a model for human disease. Oncol Lett 15, 8195-8205
  17. Lee KH, Park HM, Son KH, Shin TJ and Cho JY (2018) Transcriptome signatures of canine mammary gland tumors and its comparison to human breast cancers. Cancers (Basel) 10, 317 https://doi.org/10.3390/cancers10090317
  18. Tavasoly A, Golshahi H, Rezaie A and Farhadi M (2013) Classification and grading of canine malignant mammary tumors. Vet Res Forum 4, 25-30
  19. Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B and Aebersold R (2011) On the development of plasma protein biomarkers. J Proteome Res 10, 5-16 https://doi.org/10.1021/pr1008515
  20. Kosek AB, Durbin D and Jonas A (1999) Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem Biophys Res Commun 258, 548-551 https://doi.org/10.1006/bbrc.1999.0690
  21. Cedo L, Reddy ST, Mato E, Blanco-Vaca F and Escola-Gil JC (2019) HDL and LDL: potential new players in breast cancer development. J Clin Med 8, 853 https://doi.org/10.3390/jcm8060853
  22. Ozmen HK and Askin S (2013) Lecithin: cholesterol acyltransferase and na (+)-k (+)-ATPase activity in patients with breast cancer. J Breast Cancer 16, 159-163 https://doi.org/10.4048/jbc.2013.16.2.159
  23. Beeghly-Fadiel A, Khankari NK, Delahanty RJ et al (2019) A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. Int J Epidemiol 49, 1117-1131
  24. Jiang JT, Xu N and Wu CP (2007) Metabolism of high density lipoproteins in liver cancer. World J Gastroenterol 13, 3159-3163 https://doi.org/10.3748/wjg.v13.i23.3159
  25. Wisniewski JR, Zougman A, Nagaraj N and Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6, 359-362 https://doi.org/10.1038/nmeth.1322
  26. Kim YI, Ahn JM, Sung HJ et al (2016) Meta-markers for the differential diagnosis of lung cancer and lung disease. J Proteomics 148, 36-43 https://doi.org/10.1016/j.jprot.2016.04.052
  27. Cho HM, Kim PH, Chang HK et al (2017) Targeted genome engineering to control VEGF expression in human umbilical cord blood-derived mesenchymal stem cells: potential implications for the treatment of myocardial infarction. Stem Cells Transl Med 6, 1040-1051 https://doi.org/10.1002/sctm.16-0114